{"entity":{"id":"monte-rosa","kind":"company","name":"Monte Rosa Therapeutics","aka":[],"tldr":"Molecular-glue degrader company with a GSPT1 degrader in phase 2 for AR-mutant prostate cancer and a CCNE1-directed glue in preclinical development.","summary":"MRT-2359 (GSPT1) first patient dosed in phase 2 MODeFIRe-1 with apalutamide in AR-mutation-positive mCRPC (August 2026). AACR 2026: CCNE1-directed glue degrader produced regressions in CCNE1-amplified ovarian, breast, and gastric models with better selectivity than CDK2 inhibitors. QuEEN discovery engine; Novartis and Roche partnerships.","asOf":"2026-09-04","links":[{"label":"MODeFIRe-1 first patient","url":"https://www.globenewswire.com/news-release/2026/08/24/3349601/0/en/monte-rosa-therapeutics-announces-first-patient-dosed-in-modefire-1-a-phase-2-study-of-mrt-2359-in-combination-with-apalutamide-in-patients-with-ar-mutation-positive-metastatic-cas.html"}],"tags":[],"related":[],"cancers":["prostate","ovarian"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":["androgen-receptor"],"drugs":[],"companies":["novartis","roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07745361","nct05546268"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.monterosatx.com","ticker":"GLUE","investors":["cancer-research-horizons"],"funding":[]},"route":"/companies/monte-rosa/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}],"company":[{"id":"cancer-research-horizons","kind":"company","name":"Cancer Research Horizons","route":"/companies/cancer-research-horizons/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"trial":[{"id":"nct05546268","kind":"trial","name":"Study of Oral MRT-2359 in Selected Cancer Patients","route":"/trials/nct05546268/"},{"id":"nct07745361","kind":"trial","name":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer","route":"/trials/nct07745361/"}],"bottleneck":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}],"idea":[{"id":"idea-moon-open-degrader-consortium","kind":"idea","name":"An open degrader consortium against every undruggable driver transcription factor","route":"/ideas/idea-moon-open-degrader-consortium/"},{"id":"idea-bio2-brain-penetrant-glue-degraders","kind":"idea","name":"Design protein degraders small enough to get into the brain","route":"/ideas/idea-bio2-brain-penetrant-glue-degraders/"},{"id":"idea-bio1-myc-max-molecular-glue","kind":"idea","name":"Molecular glues that break the MYC-MAX partnership","route":"/ideas/idea-bio1-myc-max-molecular-glue/"},{"id":"idea-bio1-glue-degrader-atlas","kind":"idea","name":"Screen glue-like compounds against every cancer cell line and publish it","route":"/ideas/idea-bio1-glue-degrader-atlas/"}]}}